[go: up one dir, main page]

AR105911A1 - Inhibidores de hdac8 bicíclicos fusionados [6,6] - Google Patents

Inhibidores de hdac8 bicíclicos fusionados [6,6]

Info

Publication number
AR105911A1
AR105911A1 ARP160102695A ARP160102695A AR105911A1 AR 105911 A1 AR105911 A1 AR 105911A1 AR P160102695 A ARP160102695 A AR P160102695A AR P160102695 A ARP160102695 A AR P160102695A AR 105911 A1 AR105911 A1 AR 105911A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocycle
cycloalkyl
heteroaryl
aryl
Prior art date
Application number
ARP160102695A
Other languages
English (en)
Inventor
W Bair Kenneth
Barczak Nicholas
Lancia David Jr
Rudnitskaya Aleksandra
Liu Cuixian
Zablocki Mary
R Margaret - Thomason Jennifer
Han Bingsong
Yee Ng Pui
Zheng Xiaozhang
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of AR105911A1 publication Critical patent/AR105911A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), y sus sales, profármacos, solvatos, hidratos, isómeros o tautómeros farmacéuticamente aceptables, en donde: Y¹, Y², Y³ e Y⁴ son cada uno, de modo independiente, N, C o CR³, siempre que, cuando unidos a -C(O)NHOH, cualquiera de Y¹, Y², Y³ o Y⁴ sea C; X se selecciona del grupo que consiste en S(O)₂, S(O), S, O, C(=O) y C(R⁴)(R⁵); W es C(R⁴)(R⁵) u O; R¹ es, de modo independiente, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros, -(CH₂)ₙ-Rᵃ, -(CH₂)ₙ-O-(CH₂)ₚ-Rᵃ, -S(O)₂Rᵃ, -C(O)Rᵃ, o -C(O)N(Rᵃ)(Rᵇ), en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo o heterociclo está opcionalmente sustituido con uno o más -OH, halógeno, oxo, -NO₂, -NH₂, -CN, -alquilo C₁₋₆, -alcoxi C₁₋₆, heterociclo, arilo, heteroarilo, o R⁴; Rᵃ es, en cada ocurrencia, hidrógeno, halógeno, OH, NH₂, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros, o -C(O)N(R¹⁰)(R¹¹), en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo, o heterociclo es opcionalmente sustituido con uno o más -OH, R⁴’, R⁵’, halógeno, oxo, (CH₂)ₙOR⁶, -NO₂, -OR⁶, -N(R⁶)(R⁷), C(O)OR⁶, -C(O)N(R⁶)(R⁷), -S(O)₂R⁶, -S(O)R⁶, -S(R⁶), -C(O)R⁶, S(O)₂N(R⁶)(R⁷), -CN, alquilo -C₁₋₆, haloalquilo -C₁₋₆, alcoxi -C₁₋₆, alquilamino C₁₋₆, dialquilamino C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo C₃₋₈, cicloalquilalquilo C₃₋₈, arilalquilo, heterociclo, arilo, o heteroarilo; Rᵇ es, en cada ocurrencia, hidrógeno, halógeno, OH, NH₂, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros, o -C(O)N(R¹⁰)(R¹¹), en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo, o heterociclo es opcionalmente sustituido con uno o más -OH, R⁴’, R⁵’, halógeno, oxo, (CH₂)ₙOR⁶, -NO₂, -OR⁶, -N(R⁶)(R⁷), C(O)OR⁶, -C(O)N(R⁶)(R⁷), -S(O)₂R⁶, -S(O)R⁶, -S(R⁶), -C(O)R⁶, -S(O)₂N(R⁶)(R⁷), -CN, alquilo -C₁₋₆, haloalquilo -C₁₋₆, alcoxi -C₁₋₆, alquilamino C₁₋₆, dialquilamino C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo C₃₋₈, cicloalquilalquilo C₃₋₈, arilalquilo, heterociclo, arilo, o heteroarilo; o Rᵃ y Rᵇ se pueden combinar con el carbono o nitrógeno al que están unidos para formar un cicloalquilo C₃₋₈ o heterociclo de 3 a 8 miembros opcionalmente sustituido con uno o más sustituyentes seleccionados de R⁴’ y R⁵’, en donde R⁴’ y R⁵’ de modo independiente en cada ocurrencia son H o alquilo -C₁₋₆; R² y R²’ son, de modo independiente, hidrógeno, alquilo C₁₋₆, alcoxi C₁₋₆, -OH, halógeno, -NO₂, -NH₂, -CN, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros, en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo o heterociclo está opcionalmente sustituido con uno o más -OH, halógeno, oxo, -NO₂, -NH₂, -CN, -alquilo C₁₋₆, -alcoxi C₁₋₆; o R² y R²’ se pueden combinar con el carbono al que están unidos para formar un grupo oxo, cicloalquilo C₃₋₈ o heterociclo de 3 a 8 miembros; R³ es, de modo independiente, en cada aparición, hidrógeno, halógeno, OH, CN, NO₂, NH₂, alquilo C₁₋₃ o alcoxi C₁₋₃; cada R⁴ o R⁵ es cada uno, de modo independiente, en cada aparición, hidrógeno, halógeno, OH, NH₂, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros o -C(O)N(R¹⁰)(R¹¹), en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo o heterociclo está opcionalmente sustituido con uno o más -OH, R⁴’, R⁵’, halógeno, oxo, -(CH₂)ₙOR⁶, -NO₂, -OR⁶, -N(R⁶)(R⁷), C(O)OR⁶, -C(O)N(R⁶)(R⁷), -S(O)₂R⁶, -S(O)R⁶, -S(R⁶), -C(O)R⁶, -S(O)₂N(R⁶)(R⁷), -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -alcoxi C₁₋₆, alquil C₁₋₆-amino, dialquil C₁₋₆-amino, hidroxi C₁₋₆-alquilo, cicloalquilo C₃₋₈, cicloalquil C₃₋₈-alquilo, arilalquilo, heterociclo, arilo o heteroarilo; o R⁴ y R⁵ se pueden combinar con el carbono o nitrógeno al que están unidos para formar un grupo oxo, cicloalquilo C₃₋₈ o heterociclo de 3 a 8 miembros, opcionalmente sustituido con uno o más sustituyentes seleccionados de R⁴’ y R⁵’, en donde R⁴’ y R⁵’, de modo independiente, en cada ocurrencia, son H o alquilo -C₁₋₆; o R⁴’ y R⁵’ juntos cuando se unen al mismo átomo forman un anillo spirocicloalquilo C₃₋₈; o R⁴’ y R⁵’ juntos cuando se unen al mismo átomo forman un anillo spiroheterocicloalquilo C₃₋₈; o R⁴’ y R⁵’ juntos cuando se unen a átomos adyacentes forman un anillo arilo, un anillo heteroarilo, un anillo cicloalquilo C₃₋₈, o un heterociclo de 3 a 8 miembros, en donde el spirocicloalquilo, spiroheterocicloalquilo, heteroarilo, cicloalquilo o heterociclo son sustituidos opcionalmente con uno o más grupos seleccionados de OH, halógeno, alquilo -C₁₋₆ o C(O)OR⁶; R⁶ y R⁷ están seleccionados cada uno, de modo independiente, del grupo que consiste en hidrógeno, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, amino, alquilamino C₁₋₆, dialquilamino C₁₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₃₋₈, arilo, heteroarilo, heterociclo, -S(O)₂NR⁸R⁹, -S(O)₂R⁸, -C(O)R⁸, -CO₂R⁸, -S(O)R⁸ o -S(O)NR⁸R⁹, en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, fenilo, heteroarilo o heterociclo está opcionalmente sustituido con uno o más -OH, halógeno, oxo, -NO₂, -NH₂, -CN, -alquilo C₁₋₆, -alcoxi C₁₋₆, alquil C₁₋₆-amino, dialquil C₁₋₆-amino, hidroxi C₁₋₆-alquilo, heterociclo, arilo, heteroarilo; o R⁶ y R⁷ junto con un átomo al que están unidos forman un cicloalquilo C₃₋₈ o un heterociclo de 3 a 8 miembros, en donde el cicloalquilo o el heterociclo es sustituido opcionalmente con uno o más grupos seleccionados de halógeno, oxo y alquilo C₁₋₆; R⁸ y R⁹ son cada uno, de modo independiente, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₃₋₈, heteroarilo o heterociclo de 3 a 8 miembros, en donde cada uno está opcionalmente sustituido con uno o más -OH, halógeno, oxo, -NO₂, -NH₂, -CN, -alquilo C₁₋₆, -alcoxi C₁₋₆, alquil C₁₋₆-amino, dialquil C₁₋₆-amino, hidroxi C₁₋₆-alquilo, heterociclo, arilo o heteroarilo; R¹⁰ y R¹¹ son cada uno, de modo independiente, hidrógeno, alquilo C₁₋₆, arilo, alquil C₁₋₆-arilo o heterociclo de 3 a 8 miembros; en donde arilo, arilalquilo y heterociclo son sustituidos opcionalmente con uno o más grupos seleccionados de halógeno, alquilo C₁₋₆, y alcoxi C₁₋₆; o R¹⁰ y R¹¹ se pueden combinar para formar un heterociclo de 3 a 8 miembros opcionalmente sustituido con uno o más R¹²; R¹² es H o alquilo C₁₋₆ o dos adyacentes R¹² se pueden combinar para formar un grupo arilo o heteroarilo; n es un número entero de 1 a 6; y p es un número entero de 0 a 2; siempre que el compuesto no sea N-hidroxi-1-((4-metoxifenil)sulfonil)-1,2,3,4-tetrahidroquinolin-6-carboxamida.
ARP160102695A 2015-09-03 2016-09-02 Inhibidores de hdac8 bicíclicos fusionados [6,6] AR105911A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562214101P 2015-09-03 2015-09-03

Publications (1)

Publication Number Publication Date
AR105911A1 true AR105911A1 (es) 2017-11-22

Family

ID=56920943

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102695A AR105911A1 (es) 2015-09-03 2016-09-02 Inhibidores de hdac8 bicíclicos fusionados [6,6]

Country Status (4)

Country Link
US (5) US10029995B2 (es)
AR (1) AR105911A1 (es)
TW (1) TW201711999A (es)
WO (1) WO2017040963A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EA201792028A1 (ru) 2015-03-13 2018-04-30 Форма Терапьютикс, Инк. Альфа-цинамидные соединения и композиции как ингибиторы hdac8
TW201711999A (zh) 2015-09-03 2017-04-01 佛瑪治療公司 ﹝６，６﹞稠合雙環組蛋白脫乙醯基酶８（ｈｄａｃ８）抑制劑
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP7296954B2 (ja) 2017-06-22 2023-06-23 キュラデブ・ファーマ・リミテッド ヒトｓｔｉｎｇの小分子調節因子
JP2020524717A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
WO2019023165A1 (en) * 2017-07-24 2019-01-31 Isocure Biosciences Inc. MUTANT ISOCITRATE DEHYDROGENASE INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO
GB2568549A (en) * 2017-11-21 2019-05-22 Univ Leicester New compounds and uses
AU2019223182B2 (en) 2018-02-26 2021-08-19 Gilead Sciences, Inc. Substituted pyrrolizine compounds as HBV replication inhibitors
CN109761968A (zh) * 2018-12-25 2019-05-17 河南师范大学 具有抗肿瘤活性的丹皮酚并苯并噁嗪类化合物及其制备方法和应用
GEP20247653B (en) 2019-12-27 2024-08-12 Lupin Ltd Substituted tricyclic compounds
WO2022120048A1 (en) * 2020-12-03 2022-06-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Hdac inhibitors
KR102870919B1 (ko) * 2022-05-03 2025-10-20 충북대학교 산학협력단 신규한 n-히드록시프로펜아미드 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
EP0623122B1 (en) 1992-01-23 1997-03-05 Pfizer Inc. Benzopyran and related LTB4-antagonists.
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5393771A (en) 1993-05-12 1995-02-28 Brisol-Myers Squibb Company 4-substituted benzopyran and related compounds
JPH09505309A (ja) 1993-11-18 1997-05-27 ワシントン・ユニバーシティ 細菌感染の治療および予防のための化合物および医薬組成物
KR0125117B1 (ko) 1994-06-15 1997-12-05 성재갑 항 에이즈(aids)효과를 갖는 신규한 인간 면역 결핍 바이러스(hiv)프로테아제 억제 화합물 및 그의 제조방법
MY113463A (en) 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
NZ285156A (en) 1994-10-13 1999-01-28 Pfizer Benzopyran and benzo-fused compounds, preparation and use as leukotriene b4 antagonists (ltb4)
US5939452A (en) 1994-10-13 1999-08-17 Pfizer Inc Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4' (LTB4) antagonists
AU5271896A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S Novel heterocyclic compounds
WO1996031500A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S Novel heterocyclic compounds
WO1996031473A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S Novel heterocyclic compounds
CA2217194A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S Novel heterocyclic compounds
WO1996031470A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S Novel heterocyclic compounds
ATE219765T1 (de) 1995-04-10 2002-07-15 Fujisawa Pharmaceutical Co Indolderivate als cgmp-pde inhibitoren
WO1997049684A1 (en) 1996-06-24 1997-12-31 Novo Nordisk A/S Factor vii-binding reagent
JPH10259176A (ja) * 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
US6461610B1 (en) 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
IL128731A0 (en) 1998-03-12 2000-01-31 Pfizer Prod Inc Method of preventing allograft rejection
EP0963755A3 (en) 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
US6777413B2 (en) 2000-02-01 2004-08-17 Millennium Pharmaceuticals, Inc. 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa
EP1255743A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
AU2002306687A1 (en) 2001-03-13 2002-09-24 Glenmark Pharmaceuticals Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
US7615640B2 (en) 2002-07-29 2009-11-10 Mitsubishi PaperMillsLtd. Organic dye, photoelectric conversion material, semiconductor electrode and photoelectric conversion device
JP2008510728A (ja) 2004-08-19 2008-04-10 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
RU2008110908A (ru) 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Производные имидазола в качестве функционально селективных агонистов альфа2с адренорецепторов
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
KR20080052611A (ko) 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
CA2634456A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US20100173332A1 (en) 2006-09-07 2010-07-08 Auckland Uniservices Limited Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
CN101573333B (zh) * 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2008059339A2 (en) 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
US7985763B2 (en) 2007-04-10 2011-07-26 National Health Research Institutes Hepatitis C virus inhibitors
US8173675B2 (en) 2007-05-24 2012-05-08 Basf Se Substituted amino-thiourea compounds for combating animal pests
US20090136461A1 (en) 2007-11-28 2009-05-28 Moon Suk Kim Neuronal differentiation method of adult stem cells using small molecules
CN102015726B (zh) 2008-03-31 2014-07-23 C&C新药研究所 杂环衍生物
GB0818366D0 (en) 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinolin-2-one-compounds
KR101051057B1 (ko) 2008-11-11 2011-07-21 한국화학연구원 신경전구세포 또는 줄기세포의 신경세포로의 분화 유도용 조성물 및 방법
TW201022279A (en) 2008-11-14 2010-06-16 Astrazeneca Ab Chemical compounds
US8791090B2 (en) 2009-03-31 2014-07-29 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
JP2011148714A (ja) 2010-01-19 2011-08-04 Nippon Soda Co Ltd 病害防除方法
US20130045995A1 (en) 2010-04-28 2013-02-21 Christian Beier Fungicide hydroximoyl-heterocycles derivatives
BR112012033490A2 (pt) 2010-07-02 2015-09-15 Syngenta Participations Ag derivados de éter dioxima microbicida
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
KR101475168B1 (ko) 2010-09-09 2014-12-19 에프. 호프만-라 로슈 아게 암 치료용 신규 ｎ-하이드록시-벤즈아마이드
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CN102603628B (zh) 2010-12-22 2016-08-17 香港理工大学 作为抗癌试剂的喹啉衍生物
WO2012117421A1 (en) 2011-03-02 2012-09-07 Orchid Research Laboratories Ltd Histone deacetylase inhibitors
WO2012117021A2 (en) 2011-03-03 2012-09-07 Syngenta Participations Ag Novel microbiocidal oxime ethers
WO2012137224A1 (en) 2011-04-05 2012-10-11 University Of Delhi Coumarin compounds for the treatment of mycobacterial infections
EA201400237A1 (ru) 2011-08-17 2014-08-29 Мерк Э Сие Фолатные конъюгаты альбуминсвязывающих частиц
TR201819447T4 (tr) 2011-08-22 2019-01-21 Merck & Cie 18F-sakkarid-folatlar.
WO2013059582A2 (en) * 2011-10-20 2013-04-25 Nupotential, Inc. Small molecule inhibitors of histone deacteylases
WO2013059852A1 (en) 2011-10-25 2013-05-02 Kernaghan Gregory Lawrence Method of improving the acoustic response of musical instruments
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
ES2647437T3 (es) 2012-07-12 2017-12-21 Viiv Healthcare Uk Limited Compuestos y procedimientos para tratar el VIH
EP2970127B1 (en) 2013-03-14 2018-10-24 Glaxosmithkline Intellectual Property (No. 2) Limited 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
JP2016147807A (ja) 2013-06-04 2016-08-18 日本理化学工業株式会社 ヒドロキサム酸誘導体またはその塩
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
SG11201706146UA (en) 2015-02-02 2017-08-30 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EA201792028A1 (ru) 2015-03-13 2018-04-30 Форма Терапьютикс, Инк. Альфа-цинамидные соединения и композиции как ингибиторы hdac8
US9630922B2 (en) 2015-04-17 2017-04-25 Forma Therapeutics, Inc. 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
TW201711999A (zh) 2015-09-03 2017-04-01 佛瑪治療公司 ﹝６，６﹞稠合雙環組蛋白脫乙醯基酶８（ｈｄａｃ８）抑制劑
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors

Also Published As

Publication number Publication date
US10029995B2 (en) 2018-07-24
US20230406830A1 (en) 2023-12-21
US10829460B2 (en) 2020-11-10
US11414392B2 (en) 2022-08-16
US20210139439A1 (en) 2021-05-13
US20170066729A1 (en) 2017-03-09
US20190308946A1 (en) 2019-10-10
TW201711999A (zh) 2017-04-01
US20180354919A1 (en) 2018-12-13
WO2017040963A1 (en) 2017-03-09
US10370343B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
AR105911A1 (es) Inhibidores de hdac8 bicíclicos fusionados [6,6]
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR129635A2 (es) Moduladores de tetrahidropiridopirazina de gpr6
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR108356A1 (es) Derivados aromáticos de sulfonamida
AR099824A1 (es) Compuestos bicíclicos
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR081204A1 (es) Pirrolopirazinas como inhibidores de quinasas
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
PE20212253A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR104415A1 (es) Compuestos antiestrogénicos derivados de cromeno
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
AR108864A1 (es) Agentes antibacterianos
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
AR112900A1 (es) Compuesto derivado de pirazol y uso de este
AR103582A1 (es) Ciclopropabenzofuranil-piridopirazindionas
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
AR124034A1 (es) MODULADORES PPARg Y MÉTODOS DE USO
AR123884A1 (es) Compuestos moduladores del cftr, composiciones y usos de estos
HRP20080097T5 (en) Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists
AR098528A1 (es) Derivados imidazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure